Highlights Cybin Inc. OTC Markets

Equities

CLXP.F

CA23256X1006

End-of-day quote OTC Markets Other stock markets 18:00:00 2021-08-31 EDT			5-day change	1st Jan Change
2.63 ^CAD	-6.07%		+17.41%	+76.51%

05-06	Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	CI
04-17	Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	05-06	CI
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	04-16	MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	03-15	CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	03-14	MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	03-14	CI
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder	03-13	CI
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study	01-23	MT
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder	01-23	CI
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028	01-08	CI
Cybin Inc. Announces Recent Positive Phase 2 CYB003 Topline Results in MDD and Outlines Key Upcoming Milestones Across its Clinical Development Programs	01-04	CI
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting	12-06	CI
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses	11-30	CI
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-13	CI
Cybin Inc. Provides Update on its Clinical-Stage Programs and Key Upcoming Milestones Across its Development Pipeline	11-01	CI
Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose	23-10-31	CI
Small Pharma Brief: Cybin Completed Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics	23-10-23	MT
Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).	23-10-22	CI
Small Pharma Brief: Shareholders overwhelmingly voted in favour of Cybin's acquisition	23-10-19	MT
Cybin Inc. Completes Dosing in Phase 2 Study of Cyb003 for the Treatment of Major Depressive Disorder	23-10-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cybin Inc. OTC Markets

Equities

CLXP.F

CA23256X1006

Highlights

Filters